Table 5.
Affordability of 17 anticancer medicines before and after the national drug price negotiation policy
| Generic name | Annual duration of treatment (month) | Before NDPN |
After NDPN |
||
|---|---|---|---|---|---|
|
|
|
Annual cost (US$)
|
Affordability ratio
|
Annual cost (US$)
|
Affordability ratio
|
| Afatinib |
11.0 [33] |
16 406.75 |
6.36 |
2992.11 |
1.16 |
| Axitinib |
8.3 [34] |
53 281.35 |
20.67 |
4673.41 |
1.81 |
| Azacitidine |
12.0 [35] |
42 484.59 |
16.48 |
5122.43 |
1.99 |
| Anlotinib |
5.4 [36] |
14 460.06 |
5.61 |
2384.44 |
0.93 |
| Octreotide |
12.0 [37] |
17 497.51 |
6.79 |
3155.32 |
1.22 |
| Osimertinib |
8.2 [38] |
65 427.51 |
25.38 |
5687.73 |
2.21 |
| Crizotinib |
7.7 [39] |
62 275.82 |
24.16 |
5445.64 |
2.11 |
| Nilotinib |
12.0 [40] |
33 094.57 |
12.84 |
3134.06 |
1.22 |
| Pegaspargase |
12.0 [41] |
11 992.63 |
4.65 |
2161.57 |
0.84 |
| Pazopanib |
9.2 [42] |
32 615.83 |
12.65 |
3403.39 |
1.32 |
| Regorafenib |
4.8 [43] |
21 934.90 |
8.51 |
3582.70 |
1.39 |
| Ceritinib |
5.4 [44] |
36 721.37 |
14.25 |
4362.50 |
1.69 |
| Sunitinib |
5.6 [45] |
22 899.63 |
8.88 |
2274.73 |
0.88 |
| Vemurafenib |
6.9 [46] |
52 051.86 |
20.19 |
8408.38 |
3.26 |
| Cetuximab |
9.2 [47] |
107 835.71 |
41.83 |
9880.70 |
3.83 |
| Ibrutinib |
12.0 [48] |
119 140.45 |
46.22 |
12 509.75 |
4.85 |
| Ixazomib |
12.0 [49] |
50 049.87 |
19.42 |
8050.96 |
3.12 |
| Mean (SD) | 44 715.90 (30913.02) | 17.35 (11.99) | 5131.17 (2956.45) | 1.99 (1.15) | |
NDPN – national drug price negotiation, SD – standard deviation